Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis

Lipids Health Dis. 2021 Jan 18;20(1):6. doi: 10.1186/s12944-021-01431-x.

Abstract

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in cholesterol metabolism with high levels contributing to hypercholesterolemia. Cholesterol and sphingolipids are low in patients with liver cirrhosis. Purpose of this study was to find associations of plasma PCSK9 with circulating cholesterol and sphingolipid species and measures of liver disease severity in patients with liver cirrhosis.

Methods: PCSK9 protein levels were determined by ELISA in systemic vein (SVP), hepatic vein (HVP) and portal vein plasma of patients with mostly alcoholic liver cirrhosis. PCSK9 and LDL-receptor protein expression were analysed in cirrhotic and non-cirrhotic liver tissues.

Results: Serum PCSK9 was reduced in patients with liver cirrhosis in comparison to non-cirrhotic patients. In liver cirrhosis, plasma PCSK9 was not correlated with Child-Pugh score, Model for End-Stage Liver Disease score, bilirubin or aminotransferases. A negative association of SVP PCSK9 with albumin existed. PCSK9 protein in the liver did not change with fibrosis stage and was even positively correlated with LDL-receptor protein levels. Ascites volume and variceal size were not related to PCSK9 levels. Along the same line, transjugular intrahepatic shunt to lower portal pressure did not affect PCSK9 concentrations in the three blood compartments. Serum cholesterol, sphingomyelin and ceramide levels did not correlate with PCSK9. Stratifying patients by high versus low PCSK9 levels using the median as cut-off, several cholesteryl ester species were even low in the subgroup with high PCSK9 levels. A few sphingomyelin species were also reduced in the patients with PCSK9 levels above the median. PCSK9 is highly expressed in the liver but systemic, portal and hepatic vein levels were similar. PCSK9 was not correlated with the inflammatory proteins C-reactive protein, IL-6, galectin-3, resistin or pentraxin 3. Of note, HVP PCSK9 was positively associated with HVP chemerin and negatively with HVP adiponectin levels.

Conclusions: In the cohort of patients with liver cirrhosis mostly secondary to alcohol consumption high PCSK9 was associated with low levels of certain cholesteryl ester and sphingomyelin species. Positive correlations of PCSK9 and LDL-receptor protein in the liver of patients with chronic liver injury are consistent with these findings.

Keywords: Alcoholic; Ascites; Ceramide; Chemerin; Hepatitis C; Model for end-stage liver disease score; Sphingomyelin; Varices.

MeSH terms

  • Adipokines / blood
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Cholesterol / blood*
  • Cholesterol, LDL / blood
  • Chronic Disease
  • Cohort Studies
  • Female
  • Humans
  • Inflammation Mediators / blood
  • Kidney / physiopathology
  • Liver / blood supply
  • Liver / metabolism
  • Liver / physiopathology
  • Liver Cirrhosis / blood*
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / pathology*
  • Liver Cirrhosis / physiopathology
  • Male
  • Middle Aged
  • Proprotein Convertase 9 / blood
  • Proprotein Convertase 9 / metabolism*
  • Receptors, LDL / metabolism
  • Severity of Illness Index*
  • Sphingolipids / blood
  • Sphingomyelins / blood

Substances

  • Adipokines
  • Biomarkers
  • Cholesterol, LDL
  • Inflammation Mediators
  • Receptors, LDL
  • Sphingolipids
  • Sphingomyelins
  • Cholesterol
  • Proprotein Convertase 9